GSK has been granted a patent for a method to treat or prevent HIV-1 or HIV-2 in virologically suppressed patients by switching from a three-drug regimen to a two-drug regimen. The patent also covers a multilayer tablet with dolutegravir and rilpivirine. GlobalData’s report on GSK gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on GSK, Human telomerase RT biomarker was a key innovation area identified from patents. GSK's grant share as of May 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
Bilayer tablet for hiv treatment with dolutegravir and rilpivirine
A recently granted patent (Publication Number: US12011506B2) discloses a bilayer tablet designed for pharmaceutical use. The tablet consists of two layers in direct contact with each other - the first layer containing dolutegravir sodium and the second layer containing rilpivirine hydrochloride. Additionally, the bilayer tablet may include a coating, with specific compositions such as polyvinyl alcohol, titanium dioxide, macrogol/PEG, talc, yellow and red iron oxide. The coating may range from about 1 mg to about 30 mg in the tablet, with percentages varying from about 0.2% to about 6% w/w, and in some cases specifically about 3% w/w.
Furthermore, the patent specifies different variations in the composition of the bilayer tablet, such as the amount of coating present ranging from about 2% to about 4% w/w, or specifically about 3% w/w. The tablet may also include about 15 mg of film coating in a multilayer tablet configuration. These specific details outlined in the patent provide valuable information for pharmaceutical companies and researchers looking to develop similar bilayer tablets for the delivery of dolutegravir sodium and rilpivirine hydrochloride. The patent's focus on the precise composition and structure of the tablet highlights the importance of controlled drug delivery systems in the field of pharmaceuticals.
To know more about GlobalData’s detailed insights on GSK, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
